Author:
Pund Sopan,Mahajan Nilesh,Gangane Purushottam,Warokar Amol
Abstract
The Diclofenac Sodium is BCS class II drug which comes under the antipyretic class drug, and has a wide range of use. But due to its low solubility it has low dissolution rate and hence reduced bioavailability. There are several methods for the enhancement of solubility and dissolution rate. Pastillation technique is widely employed in chemical industry for solidification and better handling. Pastilles are solidified discrete units, acquired directly from the melt mass. However, this method of pastillation has not been explored for the drug delivery system yet. Literature revels that it can be used as a novel, effective and easiest method for the enhancement of solubility and dissolution rate. The selection of polymer was done by the solubility studies and Kolliphor HS 15 was used to make the pastilles of Diclofenac Sodium. Formation of pastilles were confirmed by FT-IR and further evaluated for % yield, drug contents, solubility study and dissolution test. From the results it was concluded that, solubility of Diclofenac Sodium was increased by pastillation method by 2-fold and dissolution rate was also enhanced by double than that of the drug. Thus, pastillation can be an effective and easiest method to enhance the solubility, dissolution rate and bioavailability of poorly water-soluble drugs having good permeability.
Keywords: Diclofenac Sodium, Pastillation, Kolliphor HS 15, Solubility enhancement, Solid dispersion.
Publisher
Society of Pharmaceutical Tecnocrats
Reference6 articles.
1. 1. Yellela S. R. K., "Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs," Journal of Bioequivalence & Bioavailability. 2010; 2:28-36.
2. 2. Sharma D., Soni M., Kumar S., Gupta G.D., "Solubility enhancement-eminent role in poorly soluble drugs, Research Journal of Pharmacy and Technology. 2009; 2:220-224.
3. 3. Kumar A., Sahoo S.K., Padhee K., Kochar P.S., Sathapathy A., Pathak N., "Review on solubility enhancement techniques for hydrophobic drugs," PharmacieGlobale.2011; 3:001-007.
4. 4. Pandit. PA, Chavan TT, Khandelwal RK, Oral lipid based multipurticulat epastilles:design and effect of pore former; Journal of pharmaceutical investigation, 2015: 1-9.
5. 5. Bajrachaiya R, Sang HL et al, Development of a Ternary solid dispersion formulation of LW6 to improve the invitro activity as BCRP inhibitor: prepration and in vitro/ in vivo characterization, 2019; 1-5.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献